Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

6.215 -0.825 (-11.72%)
Streaming Delayed Price Updated: 2:15 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,297,928
Open 6.620
Bid (Size) 6.210 (17)
Ask (Size) 6.220 (27)
Prev. Close 7.040
Today's Range 6.152 - 6.980
52wk Range 6.015 - 11.31
Shares Outstanding 185,583,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit revenue growth. 
Via Benzinga

Performance

YTD
-20.6%
-20.6%
1 Month
-19.3%
-19.3%
3 Month
-30.6%
-30.6%
6 Month
-11.7%
-11.7%
1 Year
-16.7%
-16.7%

More News

Read More
BioCryst To Acquire Astria Therapeutics In $700M Deal
Via Stocktwits
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
From Astria Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For August 4, 2025
Via Benzinga
Earnings Outlook For BioCryst Pharma
Via Benzinga
Earnings Scheduled For May 5, 2025
Via Benzinga
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Via MarketMinute
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
Via Benzinga
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level
Via Stocktwits
Topics Artificial Intelligence Earnings
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Exceeds Q2 2025 Expectations with Robust Revenue and Profit Growth
Via Chartmill
BioCryst (BCRX) Q2 Revenue Jumps 50%
Via The Motley Fool
BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering
Via Benzinga
BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish
Via Stocktwits
BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria
Via Chartmill
BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria
Via Chartmill
BioCryst Shares Surge To 16-Month High On Strong Q1 Results: Retail Sentiment Turns Extremely Bullish
Via Stocktwits
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
Via Benzinga
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
Via Benzinga
These stocks are gapping in today's session
Via Chartmill
Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased
Via Stocktwits
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
Via The Motley Fool
BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is BioCryst Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, BioCryst Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does BioCryst Pharmaceuticals, Inc. - Common Stock trade on?
BioCryst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock is BCRX on the Nasdaq Stock Market
What is the current price of BioCryst Pharmaceuticals, Inc. - Common Stock?
The current price of BioCryst Pharmaceuticals, Inc. - Common Stock is 6.215
When was BioCryst Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of BioCryst Pharmaceuticals, Inc. - Common Stock was at 10/14/25 02:15 PM ET
What is the market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock?
The market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock is 1.15B
How many shares of BioCryst Pharmaceuticals, Inc. - Common Stock are outstanding?
BioCryst Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.